biostudies-literatureLi PShaanxi Province Innovation Capability Support PlanLaboratory Animal Foundation ProgramNational Natural Science Foundation of China72https://www.ebi.ac.uk/biostudies/studies/S-EPMC11863571biostudies-literatureUnknown44(1)<h4>Background</h4>The emergence of targeted therapies and immunotherapy has broadened treatment options for patients with pancreatic ductal adenocarcinoma (PDAC). Despite this, traditional drug selection, predominantly relies on tumor markers and clinical staging, has underutilized these drugs due to ignoring patient genomic diversity. Patient-derived organoids (PDOs) and corresponding patient-derived organoid xenograft (PDOX) models offer a way to better understand and address this.<h4>Methods</h4>In this study, we established PDOs and PDOX models from PDAC clinical samples. These models were analyzed using immunohistochemistry, H&E staining, and genomic profiling. Drug screening with 111 FDA-approved drugs was performed on PDOs, and drug responses in PDOs and PDOX models were compared tJournal of experimental & clinical cancer research : CRCombining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatment.PMC1186357132070532 and 32270566SYDW_KY 2021-142022PT-38Li GShi CZhang YHuang MLi PMa YWang XLi MZhao YfalseCombining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatment.<h4>Background</h4>The emergence of targeted therapies and immunotherapy has broadened treatment options for patients with pancreatic ductal adenocarcinoma (PDAC). Despite this, traditional drug selection, predominantly relies on tumor markers and clinical staging, has underutilized these drugs due to ignoring patient genomic diversity. Patient-derived organoids (PDOs) and corresponding patient-derived organoid xenograft (PDOX) models offer a way to better understand and address this.<h4>Methods</h4>In this study, we established PDOs and PDOX models from PDAC clinical samples. These models were analyzed using immunohistochemistry, H&E staining, and genomic profiling. Drug screening with 111 FDA-approved drugs was performed on PDOs, and drug responses in PDOs and PDOX models were compared t2025-01-01T00:00:00Z2025 Feb2026-06-03T04:41:32.321Z2025-04-06T22:12:06.388ZS-EPMC118635714000126410.1186/s13046-025-03332-8